Erasca, Inc.
ERAS
주식 순위
#3613
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
주가
$13.45
마지막 동기화: 2026-10-16
시가총액
$4.70B
변동 (1일)
-9.58%
변동 (1년)
455.58%
국가
US
거래 Erasca, Inc. (ERAS)
카테고리
Healthcare
Erasca, Inc. (ERAS)의 EPS
June 2026 기준 EPS TTM: $-0.95
Erasca, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-0.95입니다. 2023년 말에는 회사의 EPS가 $-0.83였으며, 이는 2022년의 EPS $-1.99와 감소입니다.
Erasca, Inc.의 EPS 기록 (2019 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-0.95 | 37.68% |
| 2024 | $-0.69 | -16.87% |
| 2023 | $-0.83 | -58.29% |
| 2022 | $-1.99 | 93.20% |
| 2021 | $-1.03 | 21.18% |
| 2020 | $-0.85 | 750.00% |
| 2019 | $-0.10 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -1,923.16% |
US
|
|
| $-7.98 | 740.00% |
US
|
|
| $-5.29 | 456.84% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,020.00% |
NL
|
